Beijing Tong Ren Tang Chinese Medicine (3613) Fundamentals 2026 — P/E 14.3x, Revenue Analysis | SniperIQ
Beijing Tong Ren Tang Chinese Medicine (3613) is a HK-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of HK$5.7B, trading at HK$6.78 on the HKSE. This SniperIQ fundamentals page covers Beijing Tong Ren Tang Chinese Medicine's valuation (P/E 14.3x, P/B 1.4x), profitability (net margin 26.2%), revenue (HK
.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapHK$5.7B
P/E (TTM)14.3x
Net Margin26.2%
Revenue (FY25)HK
.5B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Beijing Tong Ren Tang Chinese Medicine's market cap?
Beijing Tong Ren Tang Chinese Medicine (3613) has a market capitalization of approximately HK$5.7B, trading at HK$6.78 on the HKSE. Market cap moves with the live share price.
What is Beijing Tong Ren Tang Chinese Medicine's P/E ratio?
Beijing Tong Ren Tang Chinese Medicine's trailing twelve-month P/E ratio is 14.3x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Tong Ren Tang Chinese Medicine?
Beijing Tong Ren Tang Chinese Medicine runs a net profit margin of 26.2%, a gross margin of 61.2%, and an operating margin of 31.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Tong Ren Tang Chinese Medicine generate?
Beijing Tong Ren Tang Chinese Medicine reported revenue of HK
.5B for fiscal year 2025, with net income of HK
97M and earnings per share (EPS) of 0.47. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Tong Ren Tang Chinese Medicine pay a dividend?
Beijing Tong Ren Tang Chinese Medicine offers a trailing dividend yield of about 5.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing Tong Ren Tang Chinese Medicine financially healthy?
Beijing Tong Ren Tang Chinese Medicine carries a debt-to-equity ratio of 0.03x and a current ratio of 19.65x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Tong Ren Tang Chinese Medicine a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Tong Ren Tang Chinese Medicine (3613) the key facts are: market cap HK$5.7B, P/E 14.3x, revenue HK
.5B, 52-week range 6.21-9.72. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Tong Ren Tang Chinese Medicine's full fundamentals live
Get Beijing Tong Ren Tang Chinese Medicine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.